Adrenocortical tumors are frequently found in the general population, and may be benign adrenocortical adenomas or malignant adrenocortical carcinomas. Unfortunately the clinical, biochemical and histopathological distinction between benign and malignant adrenocortical tumors may be difficult in the absence of widely invasive or metastatic disease, and hence attention has turned towards a search for molecular markers. The study of rare genetic diseases that are associated with the development of adrenocortical carcinomas has contributed to our understanding of adrenocortical tumorigenesis. In addition, comprehensive genomic hybridization, methylation profiling, and genome wide mRNA and miRNA profiling have led to improvements in our understanding, as well as demonstrated several genes and pathways that may serve as diagnostic or prognostic markers.
References
[1]
Sidhu, S.; Gicquel, C.; Bambach, C.P.; Campbell, P.; Magarey, C.; Robinson, B.G.; Delbridge, L.W. Clinical and molecular aspects of adrenocortical tumourigenesis. ANZ J. Surg. 2003, 73, 727–738, doi:10.1046/j.1445-2197.2003.02746.x.
[2]
Bovio, S.; Cataldi, A.; Reimondo, G.; Sperone, P.; Novello, S.; Berruti, A.; Borasio, P.; Fava, C.; Dogliotti, L.; Scagliotti, G.V.; et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocrinol. Invest. 2006, 29, 298–302.
[3]
Grumbach, M.M.; Biller, B.M.; Braunstein, G.D.; Campbell, K.K.; Carney, J.A.; Godley, P.A.; Harris, E.L.; Lee, J.K.; Oertel, Y.C.; Posner, M.C.; et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann. Intern. Med. 2003, 138, 424–429.
[4]
Song, J.H.; Chaudhry, F.S.; Mayo-Smith, W.W. The incidental adrenal mass on ct: Prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am. J. Roentgenol. 2008, 190, 1163–1168, doi:10.2214/AJR.07.2799.
[5]
De Reyniès, A.; Assié, G.; Rickman, D.S.; Tissier, F.; Groussin, L.; René-Corail, F.; Dousset, B.; Bertagna, X.; Clauser, E.; Bertherat, J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 2009, 27, 1108–1115.
[6]
Bilimoria, K.Y.; Shen, W.T.; Elaraj, D.; Bentrem, D.J.; Winchester, D.J.; Kebebew, E.; Sturgeon, C. Adrenocortical carcinoma in the united states: Treatment utilization and prognostic factors. Cancer 2008, 113, 3130–3136, doi:10.1002/cncr.23886.
[7]
Aubert, S.; Wacrenier, A.; Leroy, X.; Devos, P.; Carnaille, B.; Proye, C.; Wemeau, J.L.; Lecomte-Houcke, M.; Leteurtre, E. Weiss system revisited: A clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol. 2002, 26, 1612–1619, doi:10.1097/00000478-200212000-00009.
[8]
Weiss, L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 1984, 8, 163–169, doi:10.1097/00000478-198403000-00001.
[9]
DeLellis, R.A. Pathology and Genetics of Tumours of Endocrine Organs; IARC Press: Lyon, France, 2004; p. 320.
[10]
Pohlink, C.; Tannapfe, A.; Eichfeld, U.; Schmidt, F.; Fuhrer, D.; Paschke, R.; Koch, C.A. Does tumor heterogeneity limit the use of the weiss criteria in the evaluation of adrenocortical tumors? J. Endocrinol. Invest. 2004, 27, 565–569.
[11]
Soon, P.S.; McDonald, K.L.; Robinson, B.G.; Sidhu, S.B. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008, 13, 548–561, doi:10.1634/theoncologist.2007-0243.
[12]
Libe, R.; Bertherat, J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur. J. Endocrinol. 2005, 153, 477–487, doi:10.1530/eje.1.02004.
[13]
Fonseca, A.L.; Kugelberg, J.; Starker, L.F.; Scholl, U.; Choi, M.; Hellman, P.; Akerstrom, G.; Westin, G.; Lifton, R.P.; Bjorklund, P.; et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer 2012, 51, 949–960, doi:10.1002/gcc.21978.
[14]
Patterson, E.E.; Holloway, A.K.; Weng, J.; Fojo, T.; Kebebew, E. Microrna profiling of adrenocortical tumors reveals mir-483 as a marker of malignancy. Cancer 2011, 117, 1630–1639, doi:10.1002/cncr.25724.
[15]
Soon, P.S.; Tacon, L.J.; Gill, A.J.; Bambach, C.P.; Sywak, M.S.; Campbell, P.R.; Yeh, M.W.; Wong, S.G.; Clifton-Bligh, R.J.; Robinson, B.G.; et al. Mir-195 and mir-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin. Cancer Res. 2009, 15, 7684–7692, doi:10.1158/1078-0432.CCR-09-1587.
Gruschwitz, T.; Breza, J.; Wunderlich, H.; Junker, K. Improvement of histopathological classification of adrenal gland tumors by genetic differentiation. World J. Urol. 2010, 28, 329–334, doi:10.1007/s00345-010-0541-7.
[18]
Pluquet, O.; Hainaut, P. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 2001, 174, 1–15, doi:10.1016/S0304-3835(01)00698-X.
[19]
Hisada, M.; Garber, J.E.; Fung, C.Y.; Fraumeni, J.F., Jr.; Li, F.P. Multiple primary cancers in families with li-fraumeni syndrome. J. Natl. Cancer Inst. 1998, 90, 606–611, doi:10.1093/jnci/90.8.606.
[20]
Ohgaki, H.; Kleihues, P.; Heitz, P.U. P53 mutations in sporadic adrenocortical tumors. Int. J. Cancer 1993, 54, 408–410, doi:10.1002/ijc.2910540310.
[21]
Reincke, M.; Karl, M.; Travis, W.H.; Mastorakos, G.; Allolio, B.; Linehan, H.M.; Chrousos, G.P. P53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 1994, 78, 790–794, doi:10.1210/jc.78.3.790.
[22]
Libe, R.; Groussin, L.; Tissier, F.; Elie, C.; Rene-Corail, F.; Fratticci, A.; Jullian, E.; Beck-Peccoz, P.; Bertagna, X.; Gicquel, C.; et al. Somatic tp53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin. Cancer Res. 2007, 13, 844–850, doi:10.1158/1078-0432.CCR-06-2085.
[23]
Wagner, J.; Portwine, C.; Rabin, K.; Leclerc, J.M.; Narod, S.A.; Malkin, D. High frequency of germline p53 mutations in childhood adrenocortical cancer. J. Natl. Cancer Inst. 1994, 86, 1707–1710, doi:10.1093/jnci/86.22.1707.
[24]
Herrmann, L.J.; Heinze, B.; Fassnacht, M.; Willenberg, H.S.; Quinkler, M.; Reisch, N.; Zink, M.; Allolio, B.; Hahner, S. Tp53 germline mutations in adult patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2012, 97, E476–E485, doi:10.1210/jc.2011-1982.
[25]
Ribeiro, R.C.; Sandrini, F.; Figueiredo, B.; Zambetti, G.P.; Michalkiewicz, E.; Lafferty, A.R.; DeLacerda, L.; Rabin, M.; Cadwell, C.; Sampaio, G.; et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl. Acad. Sci. USA 2001, 98, 9330–9335.
[26]
Latronico, A.C.; Pinto, E.M.; Domenice, S.; Fragoso, M.C.; Martin, R.M.; Zerbini, M.C.; Lucon, A.M.; Mendonca, B.B. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 2001, 86, 4970–4973, doi:10.1210/jc.86.10.4970.
[27]
Gicquel, C.; Bertagna, X.; Gaston, V.; Coste, J.; Louvel, A.; Baudin, E.; Bertherat, J.; Chapuis, Y.; Duclos, J.M.; Schlumberger, M.; et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001, 61, 6762–6767.
[28]
Ragazzon, B.; Libe, R.; Gaujoux, S.; Assie, G.; Fratticci, A.; Launay, P.; Clauser, E.; Bertagna, X.; Tissier, F.; de Reynies, A.; et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010, 70, 8276–8281, doi:10.1158/0008-5472.CAN-10-2014.
[29]
DeChiara, T.M.; Robertson, E.J.; Efstratiadis, A. Parental imprinting of the mouse insulin-like growth factor ii gene. Cell 1991, 64, 849–859, doi:10.1016/0092-8674(91)90513-X.
[30]
Boulle, N.; Logie, A.; Gicquel, C.; Perin, L.; Le Bouc, Y. Increased levels of insulin-like growth factor ii (igf-ii) and igf-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 1998, 83, 1713–1720, doi:10.1210/jc.83.5.1713.
[31]
Gicquel, C.; Raffin-Sanson, M.L.; Gaston, V.; Bertagna, X.; Plouin, P.F.; Schlumberger, M.; Louvel, A.; Luton, J.P.; Le Bouc, Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: Study on a series of 82 tumors. J. Clin. Endocrinol. Metab. 1997, 82, 2559–2565, doi:10.1210/jc.82.8.2559.
[32]
Ilvesmaki, V.; Kahri, A.I.; Miettinen, P.J.; Voutilainen, R. Insulin-like growth factors (igfs) and their receptors in adrenal tumors: High igf-ii expression in functional adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 1993, 77, 852–858, doi:10.1210/jc.77.3.852.
[33]
Giordano, T.J.; Thomas, D.G.; Kuick, R.; Lizyness, M.; Misek, D.E.; Smith, A.L.; Sanders, D.; Aljundi, R.T.; Gauger, P.G.; Thompson, N.W.; et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 2003, 162, 521–531, doi:10.1016/S0002-9440(10)63846-1.
[34]
De Fraipont, F.; El Atifi, M.; Cherradi, N.; Le Moigne, G.; Defaye, G.; Houlgatte, R.; Bertherat, J.; Bertagna, X.; Plouin, P.F.; Baudin, E.; et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 2005, 90, 1819–1829.
[35]
l’Allemand, D.; Penhoat, A.; Lebrethon, M.C.; Ardevol, R.; Baehr, V.; Oelkers, W.; Saez, J.M. Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. J. Clin. Endocrinol. Metab. 1996, 81, 3892–3897, doi:10.1210/jc.81.11.3892.
[36]
Rump, P.; Zeegers, M.P.; van Essen, A.J. Tumor risk in beckwith-wiedemann syndrome: A review and meta-analysis. Am. J. Med. Genet. Part A 2005, 136, 95–104.
[37]
Lapunzina, P. Risk of tumorigenesis in overgrowth syndromes: A comprehensive review. Am. J. Med. Genet. Part C Semin. Med. Genet. 2005, 137C, 53–71, doi:10.1002/ajmg.c.30064.
[38]
Thakker, R.V. Multiple endocrine neoplasia—Syndromes of the twentieth century. J. Clin. Endocrinol. Metab. 1998, 83, 2617–2620, doi:10.1210/jc.83.8.2617.
[39]
Skogseid, B.; Larsson, C.; Lindgren, P.G.; Kvanta, E.; Rastad, J.; Theodorsson, E.; Wide, L.; Wilander, E.; Oberg, K. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 1992, 75, 76–81, doi:10.1210/jc.75.1.76.
[40]
Burgess, J.R.; Harle, R.A.; Tucker, P.; Parameswaran, V.; Davies, P.; Greenaway, T.M.; Shepherd, J.J. Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch. Surg. 1996, 131, 699–702, doi:10.1001/archsurg.1996.01430190021006.
[41]
Heppner, C.; Reincke, M.; Agarwal, S.K.; Mora, P.; Allolio, B.; Burns, A.L.; Spiegel, A.M.; Marx, S.J. Men1 gene analysis in sporadic adrenocortical neoplasms. J. Clin. Endocrinol. Metab. 1999, 84, 216–219, doi:10.1210/jc.84.1.216.
[42]
Schulte, K.M.; Mengel, M.; Heinze, M.; Simon, D.; Scheuring, S.; Kohrer, K.; Roher, H.D. Complete sequencing and messenger ribonucleic acid expression analysis of the men i gene in adrenal cancer. J. Clin. Endocrinol. Metab. 2000, 85, 441–448, doi:10.1210/jc.85.1.441.
[43]
Kjellman, M.; Kallioniemi, O.P.; Karhu, R.; Hoog, A.; Farnebo, L.O.; Auer, G.; Larsson, C.; Backdahl, M. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res. 1996, 56, 4219–4223.
Gummow, B.M.; Winnay, J.N.; Hammer, G.D. Convergence of wnt signaling and steroidogenic factor-1 (sf-1) on transcription of the rat inhibin alpha gene. J. Biol. Chem. 2003, 278, 26572–26579, doi:10.1074/jbc.M212677200.
[46]
Tissier, F.; Cavard, C.; Groussin, L.; Perlemoine, K.; Fumey, G.; Hagnere, A.M.; Rene-Corail, F.; Jullian, E.; Gicquel, C.; Bertagna, X.; et al. Mutations of beta-catenin in adrenocortical tumors: Activation of the wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005, 65, 7622–7627.
[47]
Kirschner, L.S.; Carney, J.A.; Pack, S.D.; Taymans, S.E.; Giatzakis, C.; Cho, Y.S.; Cho-Chung, Y.S.; Stratakis, C.A. Mutations of the gene encoding the protein kinase a type i-alpha regulatory subunit in patients with the carney complex. Nat. Genet. 2000, 26, 89–92, doi:10.1038/79238.
[48]
Bertherat, J.; Groussin, L.; Sandrini, F.; Matyakhina, L.; Bei, T.; Stergiopoulos, S.; Papageorgiou, T.; Bourdeau, I.; Kirschner, L.S.; Vincent-Dejean, C.; et al. Molecular and functional analysis of prkar1a and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase a expression and activity. Cancer Res. 2003, 63, 5308–5319.
[49]
Marchesa, P.; Fazio, V.W.; Church, J.M.; McGannon, E. Adrenal masses in patients with familial adenomatous polyposis. Dis. Colon Rectum 1997, 40, 1023–1028, doi:10.1007/BF02050923.
[50]
Choi, M.; Scholl, U.I.; Yue, P.; Bj？rklund, P.; Zhao, B.; Nelson-Williams, C.; Ji, W.; Cho, Y.; Patel, A.; Men, C.J.; et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011, 331, 768–772.
[51]
Bertherat, J.; Bertagna, X. Pathogenesis of adrenocortical cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23, 261–271, doi:10.1016/j.beem.2008.10.006.
[52]
Bernard, M.H.; Sidhu, S.; Berger, N.; Peix, J.L.; Marsh, D.J.; Robinson, B.G.; Gaston, V.; Le Bouc, Y.; Gicquel, C. A case report in favor of a multistep adrenocortical tumorigenesis. J. Clin. Endocrinol. Metab. 2003, 88, 998–1001, doi:10.1210/jc.2002-021117.
[53]
Stephan, E.A.; Chung, T.H.; Grant, C.S.; Kim, S.; von Hoff, D.D.; Trent, J.M.; Demeure, M.J. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol. Cancer Ther. 2008, 7, 425–431, doi:10.1158/1535-7163.MCT-07-0267.
[54]
Kjellman, M.; Larsson, C.; Backdahl, M. Genetic background of adrenocortical tumor development. World J. Surg. 2001, 25, 948–956, doi:10.1007/s00268-001-0034-3.
[55]
Gicquel, C.; Leblond-Francillard, M.; Bertagna, X.; Louvel, A.; Chapuis, Y.; Luton, J.P.; Girard, F.; Le Bouc, Y. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin. Endocrinol. 1994, 40, 465–477, doi:10.1111/j.1365-2265.1994.tb02485.x.
[56]
Beuschlein, F.; Reincke, M.; Karl, M.; Travis, W.D.; Jaursch-Hancke, C.; Abdelhamid, S.; Chrousos, G.P.; Allolio, B. Clonal composition of human adrenocortical neoplasms. Cancer Res. 1994, 54, 4927–4932.
[57]
Slater, E.P.; Diehl, S.M.; Langer, P.; Samans, B.; Ramaswamy, A.; Zielke, A.; Bartsch, D.K. Analysis by cdna microarrays of gene expression patterns of human adrenocortical tumors. Eur. J. Endocrinol. 2006, 154, 587–598, doi:10.1530/eje.1.02116.
[58]
Velazquez-Fernandez, D.; Laurell, C.; Geli, J.; Hoog, A.; Odeberg, J.; Kjellman, M.; Lundeberg, J.; Hamberger, B.; Nilsson, P.; Backdahl, M. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005, 138, 1087–1094, doi:10.1016/j.surg.2005.09.031.
[59]
Fernandez-Ranvier, G.G.; Weng, J.; Yeh, R.F.; Shibru, D.; Khafnashar, E.; Chung, K.W.; Hwang, J.; Duh, Q.Y.; Clark, O.H.; Kebebew, E. Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J. Surg. 2008, 32, 873–881, doi:10.1007/s00268-008-9521-0.
[60]
Fernandez-Ranvier, G.G.; Weng, J.; Yeh, R.F.; Khanafshar, E.; Suh, I.; Barker, C.; Duh, Q.Y.; Clark, O.H.; Kebebew, E. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch. Surg. 2008, 143, 841–846, doi:10.1001/archsurg.143.9.841.
[61]
Giordano, T.J.; Kuick, R.; Else, T.; Gauger, P.G.; Vinco, M.; Bauersfeld, J.; Sanders, D.; Thomas, D.G.; Doherty, G.; Hammer, G. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 2009, 15, 668–676.
[62]
Soon, P.S.; Gill, A.J.; Benn, D.E.; Clarkson, A.; Robinson, B.G.; McDonald, K.L.; Sidhu, S.B. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify igf2 and ki-67 as useful in differentiating carcinomas from adenomas. Endoc. Relat. Cancer 2009, 16, 573–583, doi:10.1677/ERC-08-0237.
Almeida, M.Q.; Fragoso, M.C.; Lotfi, C.F.; Santos, M.G.; Nishi, M.Y.; Costa, M.H.; Lerario, A.M.; Maciel, C.C.; Mattos, G.E.; Jorge, A.A.; et al. Expression of insulin-like growth factor-ii and its receptor in pediatric and adult adrenocortical tumors. J. Clin. Endocrinol. Metab. 2008, 93, 3524–3531, doi:10.1210/jc.2008-0065.
[65]
Fassnacht, M.; Libe, R.; Kroiss, M.; Allolio, B. Adrenocortical carcinoma: A clinician’s update. Nat. Rev. Endocrinol. 2011, 7, 323–335, doi:10.1038/nrendo.2010.235.
[66]
Kolomecki, K.; Stepien, H.; Bartos, M.; Kuzdak, K. Usefulness of vegf, mmp-2, mmp-3 and timp-2 serum level evaluation in patients with adrenal tumours. Endoc. Regul. 2001, 35, 9–16.
[67]
Szabo, P.M.; Tamasi, V.; Molnar, V.; Andrasfalvy, M.; Tombol, Z.; Farkas, R.; Kovesdi, K.; Patocs, A.; Toth, M.; Szalai, C.; et al. Meta-analysis of adrenocortical tumour genomics data: Novel pathogenic pathways revealed. Oncogene 2010, 29, 3163–3172, doi:10.1038/onc.2010.80.
[68]
Schmitt, A.; Saremaslani, P.; Schmid, S.; Rousson, V.; Montani, M.; Schmid, D.M.; Heitz, P.U.; Komminoth, P.; Perren, A. Igfii and mib1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 2006, 49, 298–307, doi:10.1111/j.1365-2559.2006.02505.x.
[69]
Morimoto, R.; Satoh, F.; Murakami, O.; Suzuki, T.; Abe, T.; Tanemoto, M.; Abe, M.; Uruno, A.; Ishidoya, S.; Arai, Y.; et al. Immunohistochemistry of a proliferation marker ki67/mib1 in adrenocortical carcinomas: Ki67/mib1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endoc. J. 2008, 55, 49–55, doi:10.1507/endocrj.K07-079.
[70]
Sbiera, S.; Schmull, S.; Assie, G.; Voelker, H.U.; Kraus, L.; Beyer, M.; Ragazzon, B.; Beuschlein, F.; Willenberg, H.S.; Hahner, S.; et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J. Clin. Endocrinol. Metab. 2010, 95, E161–E171, doi:10.1210/jc.2010-0653.
[71]
Figueiredo, B.C.; Cavalli, L.R.; Pianovski, M.A.; Lalli, E.; Sandrini, R.; Ribeiro, R.C.; Zambetti, G.; DeLacerda, L.; Rodrigues, G.A.; Haddad, B.R. Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J. Clin. Endocrinol. Metab. 2005, 90, 615–619.
[72]
Pianovski, M.A.; Cavalli, L.R.; Figueiredo, B.C.; Santos, S.C.; Doghman, M.; Ribeiro, R.C.; Oliveira, A.G.; Michalkiewicz, E.; Rodrigues, G.A.; Zambetti, G.; et al. Sf-1 overexpression in childhood adrenocortical tumours. Eur. J. Cancer 2006, 42, 1040–1043, doi:10.1016/j.ejca.2006.01.022.
[73]
Doghman, M.; Karpova, T.; Rodrigues, G.A.; Arhatte, M.; de Moura, J.; Cavalli, L.R.; Virolle, V.; Barbry, P.; Zambetti, G.P.; Figueiredo, B.C.; et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol. Endocrinol. 2007, 21, 2968–2987, doi:10.1210/me.2007-0120.
[74]
Ragazzon, B.; Assie, G.; Bertherat, J. Transcriptome analysis of adrenocortical cancers: From molecular classification to the identification of new treatments. Endoc. Relat. Cancer 2011, 18, R15–R27, doi:10.1530/ERC-10-0290.
[75]
Barreau, O.; de Reynies, A.; Wilmot-Roussel, H.; Guillaud-Bataille, M.; Auzan, C.; Rene-Corail, F.; Tissier, F.; Dousset, B.; Bertagna, X.; Bertherat, J.; et al. Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: An integrated genomic approach. J. Clin. Endocrinol. Metab. 2012, 97, E301–E311, doi:10.1210/jc.2011-1588.
[76]
Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128, 683–692, doi:10.1016/j.cell.2007.01.029.
[77]
Wright, K.D.; Gilbertson, R.J. To infinium, and beyond! Cancer Cell 2010, 17, 419–420, doi:10.1016/j.ccr.2010.04.020.
[78]
Das, P.M.; Singal, R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22, 4632–4642, doi:10.1200/JCO.2004.07.151.
[79]
Gao, Z.H.; Suppola, S.; Liu, J.; Heikkil？, P.; J？nne, J.; Voutilainen, R. Association of h19 promoter methylation with the expression of h19 and igf-ii genes in adrenocortical tumors. J. Clin. Endocrinol. Metab. 2002, 87, 1170–1176, doi:10.1210/jc.87.3.1170.
[80]
Sidhu, S.; Martin, E.; Gicquel, C.; Melki, J.; Clark, S.J.; Campbell, P.; Magarey, C.J.; Schulte, K.M.; R？her, H.D.; Delbridge, L.; et al. Mutation and methylation analysis of tp53 in adrenal carcinogenesis. Eur. J. Surg. Oncol. 2005, 31, 549–554, doi:10.1016/j.ejso.2005.01.013.
[81]
Rechache, N.S.; Wang, Y.; Stevenson, H.S.; Killian, J.K.; Edelman, D.C.; Merino, M.; Zhang, L.; Nilubol, N.; Stratakis, C.A.; Meltzer, P.S.; et al. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J. Clin. Endocrinol. Metab. 2012, 97, E1004–E1013.
[82]
Ozata, D.M.; Caramuta, S.; Velazquez-Fernandez, D.; Akcakaya, P.; Xie, H.; Hoog, A.; Zedenius, J.; Backdahl, M.; Larsson, C.; Lui, W.O. The role of microrna deregulation in the pathogenesis of adrenocortical carcinoma. Endocr. Relat. Cancer 2011, 18, 643–655, doi:10.1530/ERC-11-0082.
[83]
Doghman, M.; El Wakil, A.; Cardinaud, B.; Thomas, E.; Wang, J.; Zhao, W.; Peralta-Del Valle, M.H.; Figueiredo, B.C.; Zambetti, G.P.; Lalli, E. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microrna in childhood adrenocortical tumors. Cancer Res. 2010, 70, 4666–4675, doi:10.1158/0008-5472.CAN-09-3970.
[84]
Tombol, Z.; Szabo, P.M.; Molnar, V.; Wiener, Z.; Tolgyesi, G.; Horanyi, J.; Riesz, P.; Reismann, P.; Patocs, A.; Liko, I.; et al. Integrative molecular bioinformatics study of human adrenocortical tumors: Microrna, tissue-specific target prediction, and pathway analysis. Endocr. Relat. Cancer 2009, 16, 895–906, doi:10.1677/ERC-09-0096.
